Asset / Drug

NHLBI

Drug and asset intelligence for NHLBI with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 4
Stage: Development stage unavailable

Sponsor company

neurology pharmaceutical companies →

Recent signals(4)

ClinicalJuly 4, 2026

Study on Psoriasis and Cardiometabolic Disease Relationship Launched by NHLBI

The NHLBI has initiated a study to explore the relationship between psoriasis and cardiometabolic diseases.

ClinicalJuly 4, 2026

NHLBI Study on Dyslipidemias Evaluates Lipid Disorders and Their Impact

The NHLBI is conducting a study to evaluate individuals with dyslipidemias, focusing on lipid levels and related health risks.

ClinicalJune 29, 2026

NHLBI Launches Study on 18F-FAPI-74 PET/CT Imaging for Early Detection of Fibrosis

The NHLBI is conducting a trial to evaluate the efficacy of 18F-FAPI-74 PET/CT imaging in detecting early-stage fibrosis in heart and lung diseases.

ClinicalJune 29, 2026

Natural History Study of CADASIL Launched by NHLBI to Monitor Disease Progression

The NHLBI has initiated a long-term study to monitor the progression of CADASIL in affected individuals and healthy volunteers.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(4)

Topline Data

— NHLBI

Key milestones include participant recruitment rates and interim findings on the relationship between psoriasis and cardiometabolic outcomes.

July 4, 2026 · N/A

Topline Data

— NHLBI

Key results from the study regarding lipid levels and associated health risks, as well as any implications for new therapies.

July 4, 2026 · N/A

Topline Data

— NHLBI

Monitor trial outcomes, particularly the effectiveness of 18F-FAPI-74 in detecting fibrosis compared to existing imaging modalities.

June 29, 2026 · N/A

Topline Data

— NHLBI

Monitor results from the study visits and any findings related to disease progression and vascular health over the 9-year period.

June 29, 2026 · N/A

Indications

Psoriasis →

Therapeutic areas

CADASIL →

Cardiology →

Cardiology · Dyslipidemia →

Cardiology · Imaging →

Dermatology →

Dermatology · Psoriasis →

Dyslipidemia →

Imaging →

Neurology →

Neurology · CADASIL →

Psoriasis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.